Protein Supplementation Satiety Meta-analysis: What the Evidence Says

Protein Supplementation Satiety Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pa

3 min read · 600 wordsReviewed July 2026
Man presenting a protein shake in a plastic tumbler against a blurred nature background. - Evidence evidence guide for protein supplementation satiety meta-analysis
Photo by www.kaboompics.com on Pexels · Pexels License

Quick Answer

Protein Supplementation Satiety Meta analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public health sources, so conclusions should be framed as evidence aware guidance rather than medical advice.

Key Takeaways

  • 01This page is generated only from sources stored in the Migaku evidence knowledge base.
  • 02Current evidence mix: 2 narrative review.
  • 03Claims should be interpreted with the source type, study design, population, and publication date in mind.
  • 04This article is educational and does not replace care from a qualified clinician.

Protein Supplementation Satiety Meta-analysis: What the Evidence Says

Quick Answer

Protein Supplementation Satiety Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

  • This page is generated only from sources stored in the Migaku evidence knowledge base.
  • Current evidence mix: 2 narrative review.
  • Claims should be interpreted with the source type, study design, population, and publication date in mind.
  • This article is educational and does not replace care from a qualified clinician.

Evidence Map

Source Evidence type Level Date Identifier
Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance narrative review 3 2026-05-29 10.3390/nu18111751
The impacts of ready-to-eat-cereals and cereal fibers on gut health, body weight, and cardiometabolic health narrative review 3 2026-04-17 10.3389/fnut.2026.1717345

What The Sources Report

  • Randomized clinical trials consistently report mean weight loss ranging from approximately 15% to more than 20% of total body weight, accompanied by improvements in glycemic control, cardiometabolic risk factors, and obesity-related comorbidities. [Zambrano-Villacres Raynier (2026); evidence level 3]
  • As a result, pharmacotherapy is increasingly positioned as an important component of contemporary obesity treatment algorithms rather than a secondary or last-line option. [Zambrano-Villacres Raynier (2026); evidence level 3]
  • And for the last several decades, researchers have continued to provide evidence for the benefits of higher fiber intake, especially for cereal fibers, on an array of health outcomes, with the greatest effects reported among low-fiber consumers and consumers of Western-style diets (-). [Comerford Kevin B. (2026); evidence level 3]
  • Insoluble fibers, such as those primarily found in rice, corn, nuts, seeds, and vegetables tend to have more localized effects in the gastrointestinal tract such as by increasing fecal-bulking and fecal transit time, which can help promote bowel movement regularity and prevent constipation. [Comerford Kevin B. (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For protein supplementation satiety meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

  • Zambrano-Villacres Raynier (2026). Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance. DOI: 10.3390/nu18111751. PMCID: PMC13258902. PMID: 42280393. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13258902/
  • Comerford Kevin B. (2026). The impacts of ready-to-eat-cereals and cereal fibers on gut health, body weight, and cardiometabolic health. DOI: 10.3389/fnut.2026.1717345. PMCID: PMC13133055. PMID: 42079003. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13133055/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.

FAQ

Frequently Asked Questions

M

Medically reviewed

Last reviewed July 8, 2026 by Migaku Evidence Review

← All GuidesSupplement Reference →